Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.

摘要: BACKGROUND Preliminary evidence indicates that early tumor shrinkage (ETS) following immune checkpoint inhibitor (ICI) initiation may be associated with survival outcomes in patients advanced melanoma. ETS has not been explored as a biomarker of or patient-reported non-small cell lung cancer (NSCLC) treated ICIs. METHODS The study pooled data from NSCLC the randomized trials OAK and POPLAR (atezolizumab vs docetaxel; n=1464), single-arm atezolizumab BIRCH FIR (n=797). association between (≥10% decrease pretreatment sum-of-longest diameters target-lesions at 6 weeks) overall (OS), progression-free (PFS), time to deterioration (TDD) health-related quality-of-life (HRQoL) physical function (PF) was assessed using Cox proportional hazard analysis. RESULTS occurred 20% atezolizumab-treated within highly favorable OS (HR 0.33, p<0.001), PFS 0.31, TDD HRQoL 0.73, p=0.01) PF 0.52, p<0.001). results were replicated data. Atezolizumab-treated achieving had markedly improved compared docetaxel-treated (24-month 55% 32%); also 31% 4%). In contrast, for ETS, atezolizumab-treatment more modest 23% 20%) 3% 1%) improvement docetaxel. Overall, effect size significantly greater than (P(interaction)=0.002 P(interaction)<0.001 PFS). CONCLUSIONS is an easily measurable biomarker, predictive treatment NSCLC. Further, identifies benefit ICI therapy.